CAR T

Create Medicines’ CRT-402 cleared to enter clinic in Australia

Fri, 31 Jul 2026 09:00:00 -0400

Create Medicines Inc. has received Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human study of CRT-402, the company’s lead in vivo CAR T candidate for the treatment of autoimmune diseases.

Targeting MiT/TFE-family fusion-driven solid tumors with GPNMB-directed CAR T

Thu, 30 Jul 2026 09:00:00 -0400

CAR T-cell therapy has been highly effective in hematologic cancers but faces challenges in solid tumors due to the lack of safe, uniformly expressed surface antigens. A recent study found that the MiT/TFE-family fusion-driven glycoprotein NMB (GPNMB) is highly, homogeneously and stably expressed in primary and relapsed alveolar soft-part sarcoma (ASPS) and translocation renal cell carcinoma (tRCC).

Sail Biomedicines and J&J partner on in vivo CAR T therapies

Thu, 30 Jul 2026 09:00:00 -0400

Sail Biomedicines Inc. has established a strategic collaboration with Johnson & Johnson (J&J) to advance innovative in vivo CAR T therapies for immune-mediated diseases.

Series A financing at Tikva Allocell to advance TAVST-01

Thu, 23 Jul 2026 09:00:00 -0400

Tikva Allocell Pte. Ltd. has closed an $8 million series A financing to support its development of engineered, allogeneic cell therapies for adult and pediatric patients with solid tumors.

Verismo unveils CLDN6-targeting KIR-CAR program

Wed, 22 Jul 2026 09:00:00 -0400

Verismo Therapeutics Inc. has reported a new preclinical KIR-CAR program targeting the Claudin 6 (CLDN6) antigen to treat CLDN6-expressing solid tumors. The program is built around a CLDN6-directed binder discovered at the University of Pennsylvania Perelman School of Medicine through a Verismo-sponsored research agreement.

Valerio to collaborate with Abivax, outlines pipeline progress

Fri, 17 Jul 2026 09:00:00 -0400

Valerio Therapeutics SA has entered into a binding term-sheet with Abivax SA setting out the principal terms of an exclusive worldwide research and development collaboration to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases.

Tempest advances next-generation in vivo CAR T pipeline

Thu, 16 Jul 2026 09:00:00 -0400

Tempest Therapeutics Inc. has announced details of its pipeline of in vivo CAR T product candidates differentiated by a CD7-targeted mRNA/LNP delivery approach, with application in the fields of oncology and immunology. Tempest’s in vivo CAR T platform, CD7-targeted mRNA lipid nanoparticle (CD7-tLNP), offers broader T-cell reach, enhanced delivery efficiency and scalable in vivo CAR T.

Engineered CAR Ts block birch pollen allergy

Mon, 13 Jul 2026 09:00:00 -0400

A new strategy based on regulatory T cells (Tregs) engineered with chimeric antigen receptors (CARs) has shown that cell therapies can be directed against soluble allergens to control inflammation. The findings open a potential path toward the development of antigen-specific cell therapies for allergies caused by pollen, food allergens or dust mites.

Fate Therapeutics’ FT-839 gains IND clearance

Fri, 10 Jul 2026 09:00:00 -0400

Fate Therapeutics Inc. has obtained IND clearance from the FDA for FT-839, the company’s next-generation, off-the-shelf CAR T-cell product candidate targeting CD19 and CD38 for autoimmune diseases.

VLA-4-targeted radiopharmaceutical enhances CAR T cells in neuroblastoma

Mon, 06 Jul 2026 09:00:00 -0400

Neuroblastoma (NB) is a rare but aggressive pediatric cancer, the third most-common in children and the most frequent in babies. Researchers from the U.S. National Cancer Institute and collaborators have reported findings from their study investigating the use of [67Cu]Cu-LLP2A as radiopharmaceutical therapy before CAR T-cell treatment in preclinical models of NB.

Brightpath files IND application for BP-2202 for multiple myeloma

Fri, 03 Jul 2026 09:00:00 -0400

Brightpath Biotherapeutics Co. Ltd. has submitted an IND application to the FDA to initiate a phase I trial of BP-2202 in the U.S. (NCT07667868).

With GPNMB, CAR T makes further inroads in solid tumors

Thu, 02 Jul 2026 09:00:00 -0400

Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.

BMS’s dual CAR T-cell therapy shows efficacy in multiple myeloma

Thu, 25 Jun 2026 09:00:00 -0400

Researchers from Bristol Myers Squibb Co. (BMS) presented preclinical data on BMS-986453 (tunlucabtagene autoleucel), a dual-targeting BCMA×GPRC5D CAR T-cell therapy, in models of multiple myeloma.

Tumor irradiation promotes CAR T-cell persistence and efficacy in lung metastases models

Fri, 12 Jun 2026 09:00:00 -0400

A team of investigators at Icahn School of Medicine at Mount Sinai and collaborating institutions aimed to isolate the on-target activity of CAR T cells to target tumor cells.

T-Curx gains trial clearance for Siglec-6-targeted TCX-001

Thu, 11 Jun 2026 09:00:00 -0400

T-Curx GmbH has obtained clinical trial approval from the Swiss agency Swissmedic for the company’s nonviral lead CAR T program, TCX-001. The first-in-human phase I study will open in Switzerland, and a submission to the EMA will seek to expand the trial to sites in Germany. The study will enroll adults with relapsed or refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), including patients not eligible for stem cell transplantation.

TI-0032 induces B-cell depletion in preclinical setting

Wed, 10 Jun 2026 09:00:00 -0400

Therorna Shanghai Co. Ltd. has presented data on TI-0032, an anti-CD19 CAR circular RNA therapeutic delivered by lipid nanoparticles (LNPs) for the treatment of autoimmune and hematological disorders.

CSPC’s SYS-6063 gains Chinese trial clearance for SLE

Wed, 03 Jun 2026 09:00:00 -0400

CSPC Pharmaceutical Group Ltd. has obtained clinical trial clearance from China’s National Medical Products Administration (NMPA) for SYS-6063, an mRNA-LNP-based dual-target CAR T-cell injection for the treatment of relapsed or refractory systemic lupus erythematosus (SLE).

Series A financing at Waypoint Bio supports CAR T programs

Tue, 02 Jun 2026 09:00:00 -0400

Waypoint Bio has closed a $20 million series A financing round to support its work developing next-generation in vivo CAR T therapeutics for solid tumors using a platform that integrates AI, computer vision and spatial pooled screening.

Oricell’s OriC-902 shows robust results in HCC

Thu, 28 May 2026 09:00:00 -0400

At the ongoing European Association for the Study of the Liver 2026 annual meeting in Barcelona, researchers from Oricell Therapeutics Co. Ltd. presented data on a CAR T-cell approach targeting glypican 3 (GPC3) – OriC-902 – for the treatment of GPC3+ hepatocellular carcinoma (HCC).

Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma

Fri, 22 May 2026 09:00:00 -0400

Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is based on its Vivovec technology and designed to engineer fully human anti-B-cell maturation antigen (BCMA)/G protein-coupled receptor class C group 5 member D (GPRC5D) dual-targeting chimeric antigen receptor (CAR) T cells, for the potential treatment of multiple myeloma (MM).

FDA clears Qihan Biotech’s CAR T therapy QT-019C for clinic

Thu, 21 May 2026 09:00:00 -0400

Hangzhou Qihan Biotech Co. Ltd. has obtained IND clearance from the FDA for QT-019C, a universal allogeneic CAR T-cell therapy for autoimmune diseases. QT-019C cell injection is an off-the-shelf allogeneic CAR T-cell therapy engineered from healthy donor leukapheresis products to stably express two distinct CARs targeting CD19 and BCMA.

MD Anderson gains IND nod for CD94-targeted CAR T therapy

Mon, 18 May 2026 09:00:00 -0400

The University of Texas MD Anderson Cancer Center has received IND clearance from the FDA to initiate a phase I trial of a novel CAR T-cell therapy, JV-394, for patients with relapsed or refractory CD94-positive T/natural killer (NK) cell lymphomas.

Financing at Create Medicines to advance in vivo CAR therapies

Fri, 15 May 2026 09:00:00 -0400

Create Medicines Inc. has closed a $122 million series B funding round to support progression of its pipeline of in vivo CAR therapies across autoimmune disease and oncology. The company’s proprietary mRNA-LNP platform directly engineers T cells, NK cells and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies.

ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

Wed, 13 May 2026 09:00:00 -0400

Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine, this RNA fragment without free ends surpasses their performance in both efficacy and durability, bringing it to the attention of several pioneering companies. The latest advances in circRNA presented at the 29th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) clearly surpass the performance achieved with linear mRNA.

Seed financing at Parcelbio to advance mRNA medicines

Fri, 08 May 2026 09:00:00 -0400

Parcelbio has raised $13 million in seed financing to continue its development of a new class of potent and durable mRNA medicines. The financing will support development of Parcelbio’s proprietary APEXm (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR T program for autoimmune disease.

PD-L1 CAR T cells simultaneously target tumor cells and the immunosuppressive TME in CCA

Mon, 20 Apr 2026 09:00:00 -0400

Although antibodies to PD-L1 are used in the clinic, their benefit is limited by immune exclusion within the local microenvironment. Objective response rates with anti-PD-L1 monotherapy are low due to the heterogeneity of PD-L1 expression, low tumor mutational burden and the highly immunosuppressive tumor microenvironment (TME) of cholangiocarcinoma (CCA).

CGT-19 as an approach to expand CAR T-cell therapy accessibility

Mon, 30 Mar 2026 09:00:00 -0400

The use of CAR T-cell therapy has transformed outcomes for relapsed or refractory B-cell malignancies, but access to it remains extremely limited in some countries. Cartogene Therapeutics Pvt Ltd. aimed to address this need by in-licensing CGT-19, a CD19 CAR T construct from Vector Biomed Inc.

CAR T targeting CD44E splicing variant shows potential for HCC treatment

Fri, 27 Mar 2026 09:00:00 -0400

Previously, Chinese researchers used long-read RNA sequencing to identify a unique alternative splicing variant of CD44 transmembrane protein, named CD44E, which is highly expressed in hepatocellular carcinoma (HCC) tumors compared to adjacent nontumoral liver tissues. In a new study, the team analyzed the Genotype-Tissue Expression (GTEx) database and confirmed that CD44E expression is limited in essential normal organs, while CD44S standard isoform is broadly expressed on most cell types.

Approach to enhance CAR T efficacy in infectious diseases and cancer

Thu, 26 Mar 2026 09:00:00 -0400

CAR T-cell therapy can be applied to treat some chronic infectious diseases, particularly to provide a functional cure for HIV-1 in people living with HIV. However, the effectiveness of CAR T cells for persistent suppression of HIV still faces many constraints, including the high mutation rate of reverse transcriptase, which enables the emergence of immune escape viral variants.

Overt Bio advances OVT-101 toward clinic

Tue, 24 Mar 2026 09:00:00 -0400

Overt Bio Inc. is advancing lead asset OVT-101 toward the clinic. The allogeneic, potential first-in-class, off-the-shelf γδ CAR T therapy targets claudin-6, which is present in the majority of ovarian cancers and several other solid tumors.